CRISPR Therapeutics (NASDAQ: CRSP) has significantly underperformed broader equities over the past five years.
Some will argue the company’s value — its market cap is $5.7 billion as of writing — is still too high given the fundamentals of the business
CRISPR Therapeutics generates little revenue, is consistently unprofitable, and hasn’t earned significant late-stage clinical wins over the past couple of years. However, despite all that, CRISPR Therapeutics could be an attractive buy-and-hold option. Let’s consider three reasons why the biotech is worth serious consideration. 1.
Multiple catalysts on the way CRISPR Therapeutics specializes in developing gene editing therapies. This technology has already helped unlock groundbreaking medicines for otherwise difficult-to-treat conditions. However, we are arguably still in the early innings of the gene-editing revolution in the biotech industry, as the U.S.